The HonorHealth Research Institute and HonorHealth announced today the successful enrollment on a novel combination of atovaquone and azithromycin in patients with moderate-to-severe COVID-19 infection.
The clinical trial, conducted in collaboration with the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, is funded as an investigator-initiated clinical trial by HonorHealth Research Institute. This is one of 10 clinical trials that the HonorHealth Research Institute is working on related to COVID-19 to understand the biology, spread and treatment of COVID-19.
" We are excited to launch this trial in patients with COVID-19 infection. The combination of atovaquone and azithromycin has been previously studied in other infectious conditions and we hope that if proven active, it may represent a well-tolerated option for patients infected with COVID-19 ," said Michael S. Gordon, M.D., Medical Director of HonorHealth Research Institute and co-Principal Investigator of the trial.
This is the first trial in the United States, and the first trial made available to patients in Arizona, that involves this specific combination of therapies.
We are proud to be supporting this 'home grown' innovation here at the Institute, where we have been working with other front line providers, scientists and experts across the globe to bring several COVID-19 trials up in record time to support our patients and providers amid this pandemic. Kiran Avancha, PhD, RPh, Chief Operating Officer, HonorHealth Research Institute
The combination of atovaquone and azithromycin has the advantage of less risk of cardiac side effects compared to other potential COVID-19 treatments. Laboratory modeling suggests that atovaquone may be an active drug in the treatment of COVID-19 and its combination with azithromycin, studied in the rare infectious disease babesiosis, makes this an intriguing combination to study in COVID-19. Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology